Amino-Pyrrolidine Tricarboxylic Acids Give New Insight into Group III Metabotropic Glutamate Receptor Activation Mechanism

• Published in: Molecular pharmacology Vol. 71; no. 3; pp. 704 - 712
• Main Authors: Frauli, Mélanie, Hubert, Nadia, Schann, Stephan, Triballeau, Nicolas, Bertrand, Hugues-Olivier, Acher, Francine, Neuville, Pascal, Pin, Jean-Philippe, Prézeau, Laurent
• Format: Journal Article
• Language: English
• Published: United States American Society for Pharmacology and Experimental Therapeutics 01.03.2007
• Subjects: Animals; Binding Sites; Calcium; Calcium - metabolism; Cells, Cultured; Humans; Life Sciences; Models, Molecular; Mutagenesis, Site-Directed; Neurons and Cognition; Pharmaceutical sciences; Pyrrolidines; Pyrrolidines - pharmacology; Rats; Receptors, Metabotropic Glutamate; Receptors, Metabotropic Glutamate - agonists; Structure-Activity Relationship; Tricarboxylic Acids; Tricarboxylic Acids - pharmacology; groupe III; activation; glutamate; mGluR; pharmacology
• ISSN: 0026-895X; 1521-0111
• DOI: 10.1124/mol.106.030254

Like most class C G-protein-coupled receptors, metabotropic glutamate (mGlu) receptors possess a large extracellular domain where orthosteric ligands bind. Crystal structures revealed that this domain, called Venus FlyTrap (VFT), adopts a closed or open conformation upon agonist or antagonist binding, respectively. We have described amino-pyrrolidine tricarboxylic acids (APTCs), including (2 S ,4 S )-4-amino-1-[( E )-3-carboxyacryloyl]pyrrolidine-2,4-dicarboxylic acid (FP0429), as new selective group III mGlu agonists. Whereas FP0429 is an almost full mGlu4 agonist, it is a weak and partial agonist of the closely related mGlu8 subtype. To get more insight into the activation mechanism of mGlu receptors, we aimed to elucidate why FP0429 behaves differently at these two highly homologous receptors by focusing on two residues within the binding site that differ between mGlu4 and mGlu8. Site-directed mutagenesis of Ser157 and Gly158 of mGlu4 into their mGlu8 homologs (Ala) turned FP0429 into a weak partial agonist. Conversely, introduction of Ser and Gly residues into mGlu8 increased FP0429 efficacy. Docking of FP0429 in mGlu4 VFT 3D model helped us characterize the role of each residue. Indeed, mGlu4 Ser157 seems to have an important role in FP0429 binding, whereas Gly158 may allow a deeper positioning of this agonist in the cavity of lobe I, thereby ensuring optimal interactions with lobe II residues in the fully closed state of the VFT. In contrast, the presence of a methyl group in mGlu8 (Ala instead of Gly) weakens the interactions with the lobe II residues. This probably results in a less stable or a partially closed form of the mGlu8 VFT, leading to partial receptor activation.